The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday. In June 2018, the U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older. The CBD-based medicine was greenlighted in Europe
European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
[Read More ...]
Originally posted on European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says via George Scorsis Medical Marijuana News
No comments:
Post a Comment